Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

59.41 -1.36 (-2.23%)
Streaming Delayed Price Updated: 9:56 AM EDT, Jul 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 148,875
Open 58.51
Bid (Size) 59.28 (100)
Ask (Size) 59.61 (500)
Prev. Close 60.77
Today's Range 58.05 - 60.31
52wk Range 44.12 - 78.48
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis... 
Via MarketBeat
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
This new technology could one day significantly expand the market for gene-editing biotechs. 
Via The Motley Fool

Performance

YTD
+10.5%
+10.5%
1 Month
+15.1%
+15.1%
3 Month
+19.5%
+19.5%
6 Month
+2.1%
+2.1%
1 Year
+16.1%
+16.1%

More News

Read More
News headline image
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
Via The Motley Fool
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
Via The Motley Fool
Topics ETFs
News headline image
Here's How I'd Invest $10,000 Right Now ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential ↗
Via The Motley Fool
News headline image
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
Via The Motley Fool
News headline image
The Best Stocks to Invest $3,000 In Right Now ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms ↗
Via MarketBeat
Topics Intellectual Property
News headline image
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
Via The Motley Fool
News headline image
Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
Via The Motley Fool
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
Via The Motley Fool
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
Via The Motley Fool
News headline image
3 Growth Stocks That Could Generate 10X Returns ↗
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
Via MarketBeat
Topics Intellectual Property

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 59.41
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 07/08/26 09:56 AM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.69B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.